Evidence mapPaperPMID 42147162Full record

ArticleResearch square2026

TACO1 regulates mitochondrial adaptation in hypertension-induced cardiac remodeling and heart failure.

Berwin Singh Swami Vetha, Ronald McMillan, James Marchant, Mohd Mabood Khan, Joyonna Gamble-George, Jeremiah Afolabi, Edgar Garza-Lopez, Andrea G Marshall, Calixto Pablo Hernandez Perez, Dillon Garbrandt and 13 more

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Berwin Singh Swami VethaDepartment of Foundational Science, East Carolina University, Greenville, NC, USA.ORCID 0000-0002-0264-4219
Ronald McMillanDepartment of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-8363-8805
James MarchantDevelopment, Aging and Regeneration Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0002-9551-835X
Mohd Mabood KhanDepartment of Medicine, Division of Genetic Medicine & Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
Joyonna Gamble-GeorgeDepartment of Computer Science, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.ORCID 0000-0002-5492-9216
Jeremiah AfolabiDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA.
Edgar Garza-LopezDepartment of Internal Medicine, University of Iowa, Iowa City, IA, USA.
Andrea G MarshallDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0001-9997-4478
Calixto Pablo Hernandez PerezDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA.
Dillon GarbrandtDepartment of Foundational Science, East Carolina University, Greenville, NC, USA.
Bret MobleyDepartment of Pathology, Vanderbilt University Medical Center, Nashville, TN, USA.
Jenny SchaferDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0003-2505-5457
Max KushnerDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.
Oleg KovtunDepartment of Chemistry, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0001-6809-9332
Debra D MurrayDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Tonya ZeczyckiDepartment of Biochemistry and Molecular Biology, East Carolina University, Greenville, NC, USA.ORCID 0000-0002-5216-1960
Annet KiraboDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0001-8580-9359
Alexandre ColasDevelopment, Aging and Regeneration Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0001-8489-0570
Celestine WanjallaDepartment of Pharmacology and Toxicology, East Carolina University, Greenville, NC, USA.ORCID 0000-0001-9159-5414
Dao-Fu DaiDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Melanie McReynoldsThe Huck Institutes of the Life Sciences; Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA, USA.ORCID 0000-0001-5427-2739
Azeez AileruDepartment of Foundational Science, East Carolina University, Greenville, NC, USA.
Antentor HintonDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0002-7730-952X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondrial dysfunction drives hypertensive heart failure and reflects impaired oxidative phosphorylation and altered organelle structure. The mechanisms linking hypertensive signaling to mitochondrial translation and architecture remain unclear. TACO1 is a mitochondrial translational activator required for cytochrome c oxidase subunit I synthesis and may regulate respiratory chain assembly. We tested whether angiotensin II type 1 receptor activation disrupts TACO1-dependent translation and drives inner membrane remodeling. Using mRen also known as (mRen2)27 hypertensive rat hearts, we assessed mitochondrial function, ultrastructure, and metabolism. AT1R activation reduced TACO1-dependent COX I translation and produced a selective deficiency in complex IV activity. This impaired oxidative phosphorylation and increased the production of reactive oxygen species. Mitochondria exhibited reduced volume, increased fragmentation, and disrupted cristae organization with lower integrity scores. Hypertensive hearts also showed reduced expression of OPA1 and MICOS components. Metabolomic profiling separated control and heart failure groups and revealed enrichment of amino acid, nucleotide, and mitochondrial energy pathways. Lipidomic analysis identified coordinated changes across lipid classes consistent with altered membrane composition. Pharmacological AT1R inhibition restored COX I translation, rescued complex IV activity, and improved cristae structure. These findings establish a mechanistic link between hypertensive signaling, mitochondrial translation, cristae organization, and metabolic remodeling in heart failure.

Indexed as

Complex IVHypertensive heart failureMetabolic remodeling(mRen2)27 transgenic ratRenin–angiotensin systemTACO1

Identifiers

PMID42147162
PMCPMC13174799

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.